➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 4,252,792

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,252,792
Title: Injectable rabies vaccine composition and method for preparing same
Abstract:A rabies vaccine composition is disclosed which comprises a sterilized suspension of proteineous suckling mice or rat brain particles of injectable particle size laden with an amount of inactivated rabies virus which is equivalent to a virus titer of from at least about 10.sup.5 to about 10.sup.7 MLD.sub.50 per 0.01 milliliter thereof at a brain tissue concentration of from about 3 to about 6% by weight, in an aqueous buffer solution having a pH of between about 7.5 and about 8.4, and comprising an amount, dissolved therein, of between 0.03 and 0.08 moles per liter of a buffer composition comprising a mixture of an organic base of the formula ##STR1## wherein R.sub.1 and R.sub.2 each are hydrogen or CH.sub.2 CH.sub.2 OH and an acid addition salt thereof, preferably a mixture of tris (hydroxymethyl)amino methane and its hydrochloride. The vaccine composition exhibits a high potency and its pH value remains stable over a prolonged period of time.
Inventor(s): Blades; James E. (Kansas City, MO)
Assignee: Douglas Industries, Inc. (Lenexa, KS)
Application Number:06/077,498
Patent Claims:see list of patent claims

Details for Patent 4,252,792

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Glaxosmithkline Biologicals Sa RABAVERT rabies vaccine KIT 103334 1 2016-12-19   Start Trial Douglas Industries, Inc. (Lenexa, KS) 1998-12-19 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.